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Abstract
Even though anti-interferon beta (IFNb) antibodies are the main determinants of IFNb bioactivity loss and Myxovirus-
resistance protein A (MxA) is the most established marker of IFNb biological activity in IFNb-treated multiple sclerosis
patients, their usefulness in the routine clinical practice is still debated. Therefore, 118 multiple sclerosis patients naı¨ve for
treatment were enrolled for a 3-year longitudinal observational study mimicking the conditions of a real-world setting. In
order to evaluate the kinetics of bioactivity loss in blood samples obtained every 6 months after therapy initiation, MxA and
interferon receptor isoform/subunit mRNA were quantified by real-time PCR, anti-IFNb binding antibodies were detected by
radioimmunoprecipitation, and neutralizing antibodies by cytopathic effect inhibition assay. Clinical measures of disease
activity and disability progression were also obtained at all time points. We found that, at the individual-patient level, the
response to IFNb therapy was extremely heterogeneous, including patients with stable or transitory, early or late loss of
IFNb bioactivity, and patients with samples lacking MxA mRNA induction in spite of absence of antibodies. No interferon
receptor isoform alterations that could explain these findings were found. At the group level, none of these biological
features correlated with the measures of clinical disease activity or progression. However, when MxA mRNA was evaluated
not at the single time point as a dichotomic marker (induced vs. non-induced), but as the mean of its values measured over
the 6-to-24 month period, the increasing average MxA predicted a decreasing risk of short-term disability progression,
independently from the presence of relapses. Therefore, a more bioactive treatment, even if unable to suppress relapses,
reduces their severity by an amount that is proportional to MxA levels. Together with its feasibility in the routine laboratory
setting, these data warrant the quantification of MxA mRNA as a primary tool for a routine monitoring of IFNb therapy.
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Introduction
Interferon beta (IFNb) is widely used as first-line treatment for
patients with relapsing remitting multiple sclerosis (MS). Three
forms of IFNb are currently available: intramuscular IFNb-1a,
subcutaneous IFNb-1a, and subcutaneous IFNb-1b. Although the
formulation, frequency of administration, and dosage differ, all the
IFNb products are capable of reducing relapse rate by about 30%
and new MRI lesions by about 70% [1]. Effectiveness appears to
vary from patient to patient, with some of them achieving a robust
treatment response and others that respond poorly, and continue
to have clinical relapses, disability progression or active lesions on
MRI. In addition, treatment regimens that require regular
injections can be burdensome, which—together with their
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incomplete effectiveness—might lead some patients to poor long-
term compliance [2].
The heterogeneous responses and the variable compliance
represent a theoretical opportunity for a rational and personalized
use of this drug, but the optimal marker of treatment response has
still to be found, and the monitoring strategies and thresholds for
therapy switch are not thoroughly defined. Accordingly, clarifying
the response to treatment in individual patients with MS is
notoriously difficult [3,4], and several different markers have been
proposed as potential indicators of IFNb therapy success. In the
field of MRI, evidence has now accumulated to show that the
development of new lesions within 6–24 months after initiating
IFNb predicts an unfavourable response to this treatment and can
help to identify patients with a poor prognosis [5,6]. Among the
biomarkers, which were analyzed at the protein and/or mRNA
level, so far only neutralizing antibody (NAb) titers and IFNb
biological activity loss, measured by Myxovirus-resistance protein
A (MxA) mRNA quantification, have proven clinically reproduc-
ible to some degree [5]. However, some disagreement still remains,
in particular on the real role of NAb in predicting the therapeutic
efficacy of IFNb [7–9], also due to inter-laboratory variations
between NAb assays [10,11]. While, in general, the majority of the
studies have been designed in a longitudinal fashion as far as the
clinical and MRI data acquisition are concerned, the biological
information regarding IFNb bioactivity has been either collected
from different patients analyzed at single time points, or
retrospectively or based on randomized clinical trials, lacking the
information contained in longitudinal data [12]. As a conse-
quence, little evidence is available at the individual-patient level.
Therefore, to analyse IFNb bioactivity modulation in individual
patients in the conditions of a real-life setting, we designed a 3-year
prospective longitudinal study that was performed in subjects naı¨ve
for treatment initiating IFNb therapy at the time of study
inclusion. The primary outcome was the analysis of the kinetics
of IFNb bioactivity loss, defined according to MxA mRNA
induction, and of anti-IFNb antibody production. Secondary
objectives were: to evaluate whether the expression of the mRNA
for the IFNb receptor (IFNAR) subunits and isoforms had a
relevant impact on bioactivity loss; and to correlate the markers of
IFNb bioactivity with the measures of clinical disease activity, to
determine whether biomarkers can predict IFNb therapy effec-
tiveness.
Methods
Patients
For this prospective longitudinal observational study, 118
patients (36 men and 82 women, between 18 and 64 years of
age) with a diagnosis of relapsing–remitting MS according to the
McDonald criteria [13] were consecutively enrolled. To be
included, patients were required to have an Expanded Disability
Status Scale (EDSS) ranging from 0 to 4.5 and to be naı¨ve for
IFNb therapy. After enrolment, they received either intramuscular
or subcutaneous (44 mg) IFNb-1a (42 and 40 patients, respectively)
or IFNb-1b (36 patients), according to the principles of good
clinical practice. The study lasted 36 months; visits were
performed at baseline (T0), and then at 3 (T3), 6 (T6), 12 (T12),
24 (T24), 30 (T30) and 36 (T36) months of therapy. Blood was
drawn by the multiple sclerosis center nurse only after the
neurologist had verified compliance with the required time interval
(12 hours [61 hour] after the patient-declared timing of the last
IFNb injection). Patients were not receiving steroid therapy nor
showed signs of viral infection at the moment of blood draw. At all
time points, standard neurological assessments, including reporting
of relapses and careful EDSS evaluation, were also required. After
the end of the study, EDSS calculation was validated by a
neurostatus level-C certified neurologist (http://www.neurostatus.
net/).
Ethics Statement
The study was approved by the ethical committee of Spedali
Civili of Brescia (resolution n. 0863 of 12-20-2006), and all patients
signed a written informed consent.
MxA, BAb and NAb quantification
IFNb bioactivity analysis was performed by a real-time reverse
transcriptase PCR assay that measures MxA mRNA expression in
patients’ whole blood samples, as previously described [14].
Accordingly, the level of MxA mRNA induction was expressed as
relative units also called ‘‘normalization ratio’’ (NR), which
represents the fold-change in respect to MxA mRNA expression
in a standard sample of a healthy donor. BAb and NAb
quantification were performed as previously described, using a
radioimmunoprecipitation assay for BAbs [14], and a cytopathic
effect (CPE) inhibition assay for NAbs [15]. For BAb analysis, in
order to correct for the different amount of total radioactivity
obtained after each radiolabeling session, the count per minute
read for each serum was normalized as the percentage of the total
activity of that session; thus, the reported BAb levels are expressed
as ‘‘% total activity’’. BAb and MxA quantification was done in all
patients at all time points, exception made for MxA, which was not
done at T3; NAb titer was analyzed at several time points in
selected samples (149 determinations from 84 patients). The levels
of NAbs were expressed as ten-fold reduction units (TRU) [15].
Quantification of IFNAR subunits and isoforms
Primers and probes for IFNAR2 and IFNAR2.2 were from
Vitale et al. [16], while those for IFNAR1, IFNAR2.1 and
IFNAR2.3 mRNA expression were designed with Primer Express
software version 3.0 (Applied Biosystems) and were reported in
Serana et al. [17], together with the employed real-time PCR
protocol. The NR was used to express the results of IFNAR
mRNA expression.
Statistical analysis
The longitudinal analysis comparing the means between the
groups of patients treated with the three drugs over the study
period was performed by ANOVA for repeated measures based on
linear mixed models, which were fitted with a random intercept.
These models also allowed us to control for covariates, as well as to
use all available data despite patients were progressively dropping-
out (‘‘unbalanced design’’), thus enhancing the power of the
analysis and providing a less biased picture of changes over time.
For these analyses, the values of MxA, IFNAR and BAb were log-
transformed in order to obtain an approximately normal
distribution. Median EDSS changes between subgroups were
compared by the Kruskal-Wallis and Mann-Whitney tests (used
also to compare the area under the curve of non-transformed MxA
values); annualized relapse rates were analyzed by negative
binomial regression; proportions were compared by the Fisher’s
exact test. To identify factors associated to the risk of disability
progression, logistic multivariable regression was performed.
Several covariates including the age, basal EDSS, type of IFNb
treatment, presence of at least one relapse at T24, arithmetic mean
of all log2-transformed MxA levels measured between T6 and
T24, BAb levels, and IFNAR expression levels, were first tested as
possible predictors in univariate fashion. When p,0.10, variables
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were retained and tested (together with their interactions) in
multivariable models. The chosen model included as predictors
the presence of at least one relapse at T24 and the ‘‘average’’ log2
MxA levels between T6 and T24 (their interaction was not
significant and thus excluded). Based on this model, and
considering that a back-transformation of the arithmetic mean of
log-values corresponds to the geometric mean of the original
values, the predicted probability of experiencing a disability
increase after 2 years in relation to the geometric mean of non-
transformed MxA NR values was calculated. P-value threshold
was set at the level of 0.05.
Results
Study population
To perform a reliable longitudinal analysis of IFNb bioactivity
over the study period, we evaluated only patients with at least two
consecutive laboratory determinations for each marker after
therapy beginning. Therefore, 18 patients who left the study
before T12 and had undergone only one MxA determination after
therapy initiation were considered early dropouts and thus
excluded from the analysis. Of the remaining 100 patients, 17
terminated the study before reaching T24, and 26 additional
patients did not complete the study extension at T36, yielding a
total dropout count of 43 subjects, which, added to the early
dropouts, makes a total of 61 dropouts (52%), with 57 subjects
(48%) completing the 3-year study period. Reasons for dropouts
are listed in Table 1 and in the legend of Figure S1, and baseline
characteristics of analyzed patients in Table S1.
MxA, BAb, and NAb levels during treatment
The median MxA mRNA level at baseline was similar to that
observed in a group of 100 healthy donors (0.78 NR; IQR:0.78–
1.34 NR vs. 0.78 NR; IQR: 0.46–1.44 NR; p = NS) [18].There-
fore, these MxA values were pooled together in order to determine
the 99th percentile (3.83 NR), which was considered the cut-off
used to classify patients as MxA mRNA induced (i.e. above the
cutoff, MxA+) or MxA mRNA non-induced (i.e. below the cut-off,
MxA2). After therapy initiation, the level of MxA mRNA
increased similarly in the three treatment groups, and stayed
constantly elevated, with minimal fluctuations, over the study
period (Figure 1A). The only significant differences were observed
at T6, when the MxA levels increased in patients receiving IFNb-
1a 44 mg s.c., and at T18, when MxA decreased in those receiving
IFNb-1b in comparison to the other two treatment groups.
Even if patients were naive for therapy, the levels of BAbs in the
samples of MS patients obtained at T0 were significantly higher
than that found in 140 healthy donors (median of % total activity:
0.98% vs. 0.62%; p,0.0001. Figure S2). Because this probably
reflects the polyclonal increase of antibody production in MS, only
the distribution of BAb values of MS patients at T0 was used to
calculate the 99th percentile, which represented the cut-off for
BAbs (% total activity:1.73%). The analysis of the kinetics of BAb
production showed that the average BAb level during the course of
treatment was higher in patients receiving IFNb-1b in comparison
to that of patients receiving IFNb-1a (p,0.001 at all time points
from T3 to T30), with a sharp and quick increase starting as early
as 3 months after therapy initiation, a peak at T6, and then a slow
decrease over the rest of the study period until reaching levels
similar to those seen in IFNb-1a-treated patients at T36
(Figure 1B). This average decrease, with a pattern highly similar
to what previously shown by Lampasona et al. [19], was not only
due to the increasing number of dropouts during the study period,
because only three BAb-positive (BAb+) patients left the study
between T6 and T24, which was the period characterized by the
sharpest fall of BAb levels. Considering all samples pooled
together, the sensitivity of BAb measurement in respect to
detecting MxA2 samples was 46%, while the specificity was 75%.
When the CPE assay was performed, a sample was considered
NAb-positive (NAb+) if it had a titer of at least 20 TRU, according
to Antonelli et al. [15]. Because NAb levels were assayed only at
selected time points, it was not possible to infer statistically tested
conclusions. However, because NAb quantification was performed
at least once for each patient, and more than once in many of the
patients in whom the other two tests suggested a likely loss of
bioactivity, a descriptive picture of the results can be drawn,
indicating that the kinetics of NAb appearance was similar to that
of BAbs, with an early rise, in particular in subjects treated with
IFNb-1b (Fig 1C).
The two classes of anti-IFNb antibodies were only partially
overlapping because while NAbs were absent in all BAb-negative
(BAb2) samples that were tested, they were found in only 32% of
BAb+ patients, most of whom (90%) were treated with IFNb-1b
(Figure S3).
mRNA expression of IFNAR subunits/isoforms
In order to test whether IFNAR subunits modulation could
have a significant impact on IFNb bioactivity, especially after 3
years of continuous receptor stimulation, as suggested in the case
of the subunit IFNAR1 [17,20], and of the isoforms IFNAR2.2
and IFNAR2.3 [21,22], we quantified the mRNA expression of all
IFNAR subunits and isoforms at all time points. The only
significant effect was a global decrease in IFNAR2.2 mRNA over
time (Figure 2A), independently of the type of IFNb administered.
However, a multivariate regression model, performed after
correcting for the presence of anti-IFNb antibodies and type of
IFNb received, showed that, on average, the MxA mRNA levels
were not influenced by modifications in the level of the isoform
IFNAR2.2, similarly to what reported by Gilli et al. [22], but,
unexpectedly, they increased with the growth of the soluble
isoform IFNAR2.3 (Figure 2B).
Analysis of the bioactivity profile at the individual-patient
level
The kinetics of MxA mRNA induction, of BAb and NAb (when
available) production was evaluated at the individual-patient level.
A conserved IFNb bioactivity would require the simultaneous
presence of MxA-induction and, preferably, absence of BAbs and
NAbs, according to the aforementioned cut-offs. Thus, the
Table 1. Dropout distribution.
Dropout fora Early (,T12)b Before T24 Before T36 Total
Adverse event 7 4 - 11
Disease worsening 4 8 2 14
Investigator decision 1 1 11 13
Lost to follow-up - 2 6 8
Non-compliance 1 - 1 2
Consent withdrawal 5 2 6 13
18 17 26 61
aSee supplementary Figure S1 for more details.
bEarly dropouts were excluded from the analysis because only one post-therapy
MxA determination was available.
T12, T24, T36: 12, 24, 36 months post-therapy initiation.
doi:10.1371/journal.pone.0094794.t001
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potentially ‘‘full biological responders’’ to IFNb therapy would be
those patients with a conserved IFNb bioactivity at all time points.
However, several intermediate situations (i.e. sporadic MxA non-
inductions or isolated antibody positivity) and changes of
bioactivity status were observed in the distinct patients during
the study period. Therefore we defined categories that could
represent the observed spectrum of bioactivity, which allowed us
to classify patients into more homogeneous subgroups (Table 2).
A first group of 63 biological responders (63%) was made up by 37
patients whose samples were MxA+, BAb2, NAb2 at all time
points, and by 19 individuals that had only one isolated, sporadic
non-induced MxA sample, in the context of a profile of high MxA-
induction and constant lack of antibodies. Of note, all of these
were being treated with IFNb-1a (14 with IFNb-1a i.m and 5 with
sc IFNb-1a). The 7 remaining patients of this group (all but one
treated with IFNb-1a i.m.), who presented with two or three non-
consecutive, sporadic MxA non-inductions, were still considered
biological responders because of the intermittent nature of their
MxA non-induction in the total absence of NAbs or other factors,
suggesting a truly significant loss of IFNb bioactivity.
A second group of likely biological responders was made by 24
patients that were characterized, for the most part, by a conserved
MxA induction, despite the presence of antibodies of the BAb class
in at least four of the seven time points analyzed, with totally
absent or below-the-cut-off (,20 TRU) NAbs. In particular, MxA
mRNA was induced at all time points regardless of BAbs in 10
patients, while one MxA non-induced sample was found in 14 of
them. In most patients BAbs appeared as early as 3 months after
therapy beginning; peaked at the subsequent time point; and then
gradually declined up to undetectable values at the end of the
follow up, so that only 7 patients had BAbs at T36. Eighteen
patients belonging to this group were treated with IFNb-1b.
A third group of 10 patients was considered biological non-
responder due to several consecutive MxA non-inductions, and
was further divided into two subcategories because of the
heterogeneity in the seeming reasons of bioactivity loss (presence
vs. absence of anti- IFNb antibodies). Indeed, the first subcategory was
made by 8 patients whose samples resulted not only MxA-non-
induced in two or more consecutive occasions, but were also
simultaneously BAb+ and NAb+; however, NAbs, which were
tested at several time points, resulted high (.200 TRU) only in 1
patient and very high (.400 TRU) in another one, and in their
remaining samples their level of MxA induction was just above the
cut-off or stayed fairly low (4,MxA,16 NR). These biological
non-responders had been treated with the highest dose of IFNb (7
with IFNb-1b and 1 with IFNb-1a 44 mg s.c). The second subcategory
of biological non-responders was a puzzling subgroup of 2 patients
treated with IFNb-1a i.m who were consecutively MxA-non-
Figure 1. Kinetics of change of MxA, BAbs, NAbs during the study period. MxA values (A) in patients treated with IFNb-1a i.m. (clear circles,
dashed grey line), IFNb-1a s.c. (clear squares, solid grey line), IFNb-1b s.c. (clear diamonds, solid black line). Average kinetics of BAb production in all
samples (B) and of NAb (C) production in selected samples in patients treated with IFNb-1a i.m. (dashed grey line), IFNb-1a s.c. (solid grey line), IFNb-
1b s.c. (solid black line). Lines connect predicted means. Arrows indicate the cut-offs. For BAbs, 95% confidence intervals are shown; for NAbs,
standard deviations are shown because confidence intervals were not calculated (no statistical inference was performed due to selection bias). MxA:
myxovirus-resistance protein A; NR: normalization ratio; BAbs: binding antibodies; NAbs: neutralizing antibodies; IFNb: interferon beta.
doi:10.1371/journal.pone.0094794.g001
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induced at nearly all time points of the study period, in the absence
of both BAbs and NAbs. Any altered IFNAR subunit/isoform
expression that could explain this seeming bioactivity loss was not
found (data not shown). In order to exclude the presence of genetic
polymorphisms that could have rendered the MxA assay falsely
negative, we have also sequenced the area bound by the real-time
PCR MxA primers and probe, without finding any differences
from the reference sequence (not shown). The kinetics of
bioactivity loss was peculiar in at least 4 of the 10 biological
non-responders: in 1 patient the bioactivity loss appeared late in
the course of treatment (after 30 months); in 2 patients treated with
IFNb-1b both BAbs and NAbs disappeared and MxA reverted
back to induction at T24 or at T30, suggesting that a late recovery
of bioactivity is possible; also in 1 of the patients who had been
repeatedly MxA-non-induced (but BAb2/NAb2), MxA reverted
back to induction, albeit at a low level, at T36.
Finally, it was identified a fourth group of 3 patients, 2 of whom
treated with IFNb-1b and 1 with IFNb-1a i.m., who showed
intermediate features and could not be included in any of the
previous schemes. Indeed, their MxA, even if sometimes low, was
always above the cut-off, despite they had BAbs in at least two
consecutive samples, and they had both BAbs and NAbs at one
time point. BAbs and NAbs, however, declined to levels below the
cut-off at the following time points, even if in 1 of these patients
NAbs were high-titered (.200 TRU). This suggests that bioactiv-
ity, if not fully, was conserved for the most part of the study period.
MxA and disability progression
The annualized relapse rate and the proportion of relapse-free
patients after 24 or 36 months of study period were calculated and
used as markers of disease activity, while an EDSS increase of at
least 1 point over a period of at least 2 years was considered a
significant marker of disability progression [23,24]. As expected,
the proportion of relapse-free patients after 2 years of treatment
was significantly higher among those who did not show disability
progression in the same time lapse (88% vs. 12%, p,0.001).
Figure 2. Role of IFNAR2.2 and IFNAR2.3 isoforms on IFNb bioactivity. Average decrease of IFNAR2.2 mRNA (A) in patients treated with
IFNb-1a i.m. (clear circles, dashed grey line), IFNb-1a s.c. (clear squares, solid grey line), IFNb-1b s.c. (clear diamonds, solid black line). Lines connect
predicted means; 95% confidence intervals are shown. Average change in MxA mRNA induction over time in dependence of different levels of
expression of IFNAR2.3 mRNA (B), as determined by multivariable mixed-model regression. IFNAR: interferon receptor; IFNb: interferon beta;MxA:
myxovirus-resistance protein A; NR: normalization ratio.
doi:10.1371/journal.pone.0094794.g002
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However, no significant associations were found between these
clinical parameters and the presence of BAbs or the absence of
MxA induction, even if patients were grouped according to the
different bioactivity profiles obtained by the individual-patient
level analysis, or if groups were pooled together to compare all
biological responder vs. all biological non-responder patients. The
only exception was a significantly different (between the four
groups) proportion of subjects with an increased EDSS after 2
years, which was likely due to the 2 biologically non-responder
patients without antibodies, who both showed a clinical worsening
(Table 3). These results suggest that the risk of disease evolution is
not clearly predicted by classifying of patients on the basis of the
MxA induction and the presence of antibodies.
However, the analysis was done considering MxA as a binary,
dichotomic variable (MxA+ vs. MxA2), determined only according
to MxA mRNA level variation across a conventional threshold,
while the amount of MxA mRNA varies in a continuous fashion
[25,26]. Thereafter, by repeated measure analysis, we compared
the MxA values that were obtained across multiple observations in
the patients with or without disability progression (10 [12%] vs. 73
[88%] patients), finding that patients showing a 1-point EDSS
increase after 2 years of treatment had a significantly lower level of
MxA induction (Figure 3A). More importantly, this difference was
independent of the type of IFNb treatment. A similar result was
obtained by calculating the area under the curve for MxA
expression from baseline to T24, which resulted lower in patients
with a 1-point increased EDSS after 2 years (Figure 3B). These
observations led to the hypothesis that a higher level of MxA
induction could be associated to a better therapeutic response to
IFNb, ultimately affecting the likelihood of EDSS worsening.
Therefore, in order to verify to what extent a higher average MxA
level could determine a reduced risk of 1-point EDSS increase, we
studied the relation between the two variables by multivariable
logistic regression. The best fitting model showed that each 1-unit
increase in the ‘‘average’’ log2MxA levels (or, in other words, each
doubling in the geometric mean of non-transformed MxA)
predicts a reduction of 47% in the risk of 1-point EDSS increase
(OR: 0.53, p = 0.02; CI: 0.30–0.92), and that the presence of at
least one relapse in the first 2 years is a very strong independent
predictor of EDSS worsening risk (OR 22.40, p = 0.001, CI:3.63–
138.11). No other covariates, including the type of IFNb
treatment, basal EDSS, bioactivity profile, and IFNAR expression
levels, had any significant impact on this risk. In particular, with
this model, it was possible to calculate that relapsed patients with a
geometric mean of MxA $16 NR have a probability of EDSS
worsening significantly lower than 50%, which is similar to that
calculated for patients without relapses (Figure 3C). A potential
limitation of this cross-sectional analysis is that it may suffer from
selection bias due to attrition, i.e. the patients dropping-out before
T24, and in particular due to the 12 subjects who left the study
because of reported disease worsening (Figure 1). While in
principle we cannot completely exclude it, this seems unlikely,
because if we evaluate the few MxA determinations performed in
these patients before they dropped-out, their average values were
higher than the proposed cut-off in only 2 of them (not shown).
Discussion
This 3-year prospective observational study was primarily
aimed to study IFNb bioactivity in a real-life setting. The primary
tool to define each patient IFNb bioactivity status was the
quantification of MxA mRNA induction, the most established
marker of IFNb bioactivity [27]. It can be performed by a simple
and reproducible real-time PCR assay [28], easily transferred to
the routine clinical practice [18].
We found that, after therapy initiation, MxA mRNA was stably
induced to a similar extent by IFNb-1a i.m., IFNb-1a 44 mg s.c.,
and IFNb-1b preparations. The analysis of MxA-induction in the
individual patients, i.e. when the MxA mRNA level was below a
cut-off, allowed us to conclude that 90/100 patients had a
conserved IFNb bioactivity, while 10/100 of patients were
biological non-responders. The pattern and kinetics of antibody
production was rather heterogeneous: in 8 of these 10 non-
responder patients the absence of MxA induction was always
accompanied by the presence of BAbs, while NAbs were above
their cut-off in the majority but not in all tested samples. This
partial discrepancy can be due to the well-known technical issues
regarding the detection and quantification of IFNb-induced NAbs
that may lead to NAb status misclassification in as much as 30% of
samples, even in reference laboratories [11]. Therefore, although
NAbs may sometimes be undetected, our result confirms that anti-
IFNb antibodies are linked to IFNb bioactivity loss. In the
remaining 2 biological (and clinical) non-responder patients
repeated MxA non-inductions were observed in total absence of
anti-IFNb antibodies. Despite Gilli et al. [21] reported the IFNAR
receptor system as a possible determinant of bioactivity loss in
Table 2. Characteristics of the patients and classification according to IFNb-bioactivity profiles.
Bioactivity profile over the follow-up Laboratory features # IFNb-1a i.m. (#) IFNb-1a s.c. (#) IFNb-1b s.c. (#)
Biological responder patients MxA+BAb2NAb2 63 33 28 2
- constantly MxA+ 37 13 22 2
- with 1/2/3 sporadic MxA2 19/4/3 14/3/3 5/1/- -
Biological responder patients with BAbs MxA+BAb+NAb2 24 1 5 18
Biological non-responder patients MxA2 10 2 1 7
- with anti-IFNb antibodies BAb+Nab+ 8 - 1 7
- without anti-IFNb antibodies BAb2NAb2 2 2 - -
Patients with intermediate features MxA/BAb/NAb +/2 3 1 - 2
TOTAL 100 37 34 29
IFNb: interferon beta.
MxA: myxovirus-resistance protein A.
BAb: binding antibodies.
NAb: neutralizing antibodies.
doi:10.1371/journal.pone.0094794.t002
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patients with similar features, we did not find any peculiar
alterations of IFNAR subunit/isoform mRNA expression in these
individuals. Overall, in our study population, IFNAR mRNA
modulation was not correlated to IFNb bioactivity loss, and in the
debate about the agonistic or antagonistic implication of the
soluble isoform [29,30], our results are in support of an agonistic
role, because higher levels of IFNAR2.3 mRNA were associated to
higher MxA values. An alternative explanation for the repeated
absence of MxA induction in total absence of anti-IFNb antibodies
could also be non-compliance. Even among the 90 patients that
were classified as biological responders there were samples
intermittently resulting MxA-non-induced within a background
of repeated MxA induction and no antibodies, nor IFNAR
alterations. Because all these patients were treated with IFNb-1a
i.m., which is administered once a week, the most likely
interpretation could be patients not correctly assuming their drug
or failure to report the correct timing of drug injection more than a
true, sporadic loss of bioactivity. The absent MxA mRNA
induction was not due to a concurrent treatment with statins that
were shown to reduce the in vitro production of MxA [31],
because only one patient assumed a drug of the statin class within
a time frame concomitant with a sample resulting MxA2BAb2-
NAb2, and only at the last point of his follow up. Another possible
explanation could be a genetic alteration in the IFNb response
genes, such as single nucleotide polymorphisms or mutations in the
MxA gene promoter or in other regulatory regions involving the
MxA response [32,33], whereas by sequencing, we could exclude
genetic alterations in the regions involved in the interaction with
the real-time PCR primers and probe. Finally, we found that a late
restoration of lost IFNb bioactivity can occasionally occur.
When analyzed at the group level, the bioactivity profiles were
for the most part unlinked from the clinical disease activity, thus
not confirming previous reports indicating that MxA quantifica-
tion can be associated to disease activity [34]. Besides differences
in the study designs (prospective vs. retrospective), this discrepancy
may arise because the classification of IFNb bioactivity loss as an
all-or-nothing phenomenon (MxA+ vs. MxA2) may not be
sensitive enough to be correlated to individual changes in clinical
disease activity in a short time interval. In this context, it had also
been previously reported by Malucchi et al. [26] in another
Figure 3. Average MxA as a potential marker of disability progression. Comparison of the log2MxA values (A) and of the area under the
curve for non-transformed MxA mRNA levels calculated over the first two years of treatment (B) between patients with or without at least 1-point
EDSS increase in the same period. Predicted probability of 1-point EDSS increase after 2 years of treatment in patients with at least one relapse (filled
circles) vs. relapse-free patients (clear circles) in the same period (C). In (A) 95% confidence intervals are shown, while the shown p-value refers to the
main effect of the ANOVA factor ‘‘1-point EDSS increase’’ (the interaction with the ‘‘time-point’’ factor was non-significant). In (B) the median,
interquartile range, and range are shown as box-and-whisker plot. AUC: area under the curve; MxA: myxovirus-resistance protein A; NR: normalization
ratio; EDSS: Expanded Disability Status Scale.
doi:10.1371/journal.pone.0094794.g003
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retrospective study that there are samples with intermediate levels
of MxA defined as ‘‘grey-zone’’ that can have a reduced, yet not
completely lost bioactivity. Indeed, we also found samples in which
MxA was slightly above the cut-off in presence of low/
intermediate titers of NAbs, indicating that bioactivity can
sometimes fluctuate between being completely lost and being
partially reduced, but not absent. These data prompted us to
analyze the IFNb bioactivity also on a continuous quantitative
scale, which might be more appropriate to represent the biological
therapy course. Accordingly, we found that in the first 2 years of
study period the average amount of MxA mRNA induction,
considered on its quantitative scale, was increased in patients with
a lower risk of having a 1-point EDSS increase, which is the EDSS
variation considered significant in describing a disability progres-
sion in our study [23,24]. In particular, the proportion of the risk
of 2-year progression that could be attributed to MxA was
independent from the presence of clinically apparent relapses,
which, by themselves, contributed as expected to this risk. As a
result, according to our prospective study, the patients with
‘‘average’’ MxA values above 16 NR in the first 2 years of
treatment, even in presence of clinically apparent relapses, had an
estimated probability of disability progression lower than 50%,
which was similar to the low probability observed in relapse-free
patients. These data indicated, for the first time, that the levels of
MxA, even if predictive of the relapse rate [25,34], are linked to a
clinical measure of disability accumulation, which, in turn, is
known to be predictive of long-term disability [24,35]. If similar
results will be confirmed by larger studies, an evaluation of MxA
on a quantitative scale may prove an efficient tool for identifying
patients at high risk of progression, in addition to the commonly
employed MRI lesion load and relapse rate.
A number of questions may arise from these findings. Because it
is obvious that not only the number but also the localization and
the severity of relapses are crucial determinants of disability
accumulation, the most likely explanation of our results could be
that a persistently bioactive treatment, even if unable to suppress
their occurrence, can reduce relapse severity by an extent that
appears correlated to increasing average MxA levels. The
quantitative monitoring of MxA may also be a more sensitive
marker of the magnitude of IFNb-mediated effects against the
basal ‘‘background’’ of inflammatory activity, where a continuous,
and not all-or-nothing anti-inflammatory effect seems more
biologically plausible, and should ultimately lead to less severe
damages. Another improvement is that the MxA assay can help
the clinicians to overcome the NAb dilemma: on one hand, in fact,
it is now widely recognized that NAbs have an impact on therapy
success at the population level, and, indeed, NAbs appeared as the
cause of MxA non-induction in the majority of our patients, even if
sometimes they were low titered and underdetected; on the other
hand, the consensus reached between the leading North American
and European neurological societies after a decade of debates
concluded that, at the individual-patient level, the interpretation of
NAb measurements can be ambiguous, and that in cases of
intermediate or low NAb titers additional information is needed,
which can be provided by MxA bioactivity measurements [9].
Finally, inconsistent results regarding the same patient’s NAb
status were obtained in four reference laboratories in as much as
30% of the samples [11]. On the contrary, the MxA mRNA assay
appears as a more practical and convenient assay, easily
standardized for the routine practice [18,28], and our results
provide a reference value to link bioactivity, clinical course, and
therapy.
Therefore, in conclusion, we propose the average MxA mRNA
quantification as a reliable marker of the IFNb long-term
response, which encompasses the severity of relapses and disability,
and can potentially stand as the primary tool to routinely monitor
IFNb therapy.
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